LC
TCON

Lindbrook Capital’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Lindbrook Capital’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$8K – 2232
2021
Q3 		$8K Sell
100
-50
-33% -$4.23K ﹤0.01% 1107
2021
Q2 		$19K Sell
150
-175
-54% -$24.2K ﹤0.01% 811
2021
Q1 		$53K Buy
+325
New +$62.6K 0.01% 429
2020
Q4 		– Sell
-500
Closed -$52K – 1901
2020
Q3 		$52K Buy
+500
New +$26.8K 0.01% 352

Other funds holding TCON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Lindbrook Capital's TCON Position: Q4 2021 in Review

Lindbrook Capital sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q4 2021, closing a stake of 100 shares — an estimated $8K sold.

Lindbrook Capital first reported a position in TCON in Q3 2020 and held it in 4 quarters. The position peaked at $53K in Q1 2021. 35 funds tracked by Wall St. Rank hold TCON as of Q4 2021.

  • Lindbrook Capital reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Lindbrook Capital sold 100 TRACON Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $8K.
  • Lindbrook Capital first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • Lindbrook Capital's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $53K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Lindbrook Capital's 13F filing for Q4 2021, filed 18 Jan 2022.